FIRESTEIN & KELLEY’S TEXTBOOK OF RHEUMATOLOGY, 2-VOLUME SET. 11TH EDITION

FIRESTEIN & KELLEY’S TEXTBOOK OF RHEUMATOLOGY, 2-VOLUME SET. 11TH EDITION

Editorial:
MOSBY
Año de edición:
Materia
Reumatología
ISBN:
978-0-323-63920-0
Páginas:
2400
N. de edición:
11
Idioma:
Inglés
Ilustraciones:
850
Disponibilidad:
Disponible en 10 días

Descuento:

-5%

Antes:

395,20 €

Despues:

375,44 €

VOLUME I
• Part 1: Structure and Function of Bone, Joints, and Connective Tissue
1. Biology of the Normal Joint, 1
2. Synovium, 20
3. Cartilage and Chondrocytes, 34
4. Biology, Physiology, and Morphology of Bone, 60
5. Muscle: Anatomy, Physiology, and Biochemistry, 67
6. Biomechanics, 80
7. Regenerative Medicine and Tissue Engineering, 92
8. Proteinases and Matrix Degradation, 109
• Part 2: Cells Involved in Autoimmune Diseases and Inflammation
9. Dendritic Cells, 132
10. Mononuclear Phagocytes, 149
11. Neutrophils, 161
12. T Lymphocytes, 182
13. B Cells, 199
14. Fibroblasts and Fibroblast-like Synoviocytes, 222
15. Mast Cells, 241
16. Innate Lymphoid Cells and Natural Killer Cells, 254
17. Platelets and Megakaryocytes, 262
• Part 3: Effector Mechanisms in Autoimmunity and Inflammation
18. Principles of Signaling, 273
19. The Immunologic Repercussions of Cell Death, 286
20. Innate Immunity, 306
21. Adaptive Immunity, 320
22. Autoimmunity and Tolerance, 337
23. The Microbiome in Health and Disease, 355
24. Metabolic Regulation of Immunity, 368
25. Genetics of Rheumatic Diseases, 378
26. Epigenetics of Rheumatic Diseases, 393
27. Complement System, 409
28. Prostaglandins, Leukotrienes, and Related Compounds, 420
29. Chemokines and Cellular Recruitment, 437
30. Angiogenesis, 445
31. Cytokines, 455
32. Experimental Models for Rheumatoid Arthritis, 467
33. Neuronal Regulation of Pain and Inflammation, 480
• Part 4: Broad Issues in the Approach to Rheumatic Disease
34. Clinical Research Methods in Rheumatic Disease, 495
35. Economic Impact of Arthritis and Rheumatic Conditions, 510
36. Assessment of Health Outcomes, 522
37. Biomarkers in Rheumatology, 536
38. Occupational and Recreational Musculoskeletal Disorders, 551
39. Cardiovascular Risk in Inflammatory Rheumatic Disease, 563
40. Cancer Risk in Rheumatic Diseases, 579
41. Introduction to Physical Medicine and Rehabilitation, 592
42. Pregnancy and Rheumatic Diseases, 604
• Part 5: Evaluation of Generalized and Localized Symptoms
43. History and Physical Examination of the Musculoskeletal System, 621
44. Ultrasound in Rheumatology, 638
45. Evaluation of Monoarticular and Polyarticular Arthritis, 663
46. Skin and Rheumatic Diseases, 678
47. The Eye and Rheumatic Diseases, 702
• Part 6: Differential Diagnosis of Regional and Diffuse Musculoskeletal Pain
48. Neck Pain, 711
49. Shoulder Pain, 727
50. Low Back Pain, 753
51. Hip and Knee Pain, 776
52. Foot and Ankle Pain, 792
53. Hand and Wrist Pain, 800
54. Temporomandibular Joint Pain, 813
55. Fibromyalgia, 825
• Part 7: Diagnostic Tests and Procedures in Rheumatic Diseases
56. Synovial Fluid Analyses, Synovial Biopsy, and Synovial Pathology, 841
57. Arthrocentesis and Injection of Joints and Soft Tissues, 859
58. Anti-nuclear Antibodies, 875
59. Autoantibodies in Rheumatoid Arthritis, 890
60. Acute Phase Reactants, 907
61.Imaging in Rheumatic Diseases, 920
• Part 8: Pharmacology of Anti-rheumatic Drugs
62. Therapeutic Targeting of Prostanoids, 965
63. Glucocorticoid Therapy, 985
64. Traditional DMARDs: Methotrexate, Lefl, Sulfasalazine, Hydroxychloroquine, and Combination Therapies, 1007
65. Immunosuppressive Drugs, 1031
66. Anti-cytokine Therapies, 1046
67. Cell-Targeted Biologics and Emerging Targets: Rituximab, Abatacept, and Other Biologics, 1068
68. Intra-cellular Targeting Agents in Rheumatic Disease, 1091
69. Urate-Lowering Therapy, 1111
70. Bisphosphonates, 1125
71. Analgesic Agents in Rheumatic Disease, 1135
72. Nutrition and Rheumatic Diseases, 1156
73. Evaluation and Management of Early Undifferentiated Arthritis, 1173

VOLUME II
• Part 9: Rheumatoid Arthritis
74. Etiology of Rheumatoid Arthritis, 1181
75. Pathogenesis of Rheumatoid Arthritis, 1200
76. Clinical Features of Rheumatoid Arthritis, 1236
77. Treatment of Rheumatoid Arthritis, 1258
78. Sjögren’s Syndrome, 1284
• Part 10: Spondyloarthritis
79. Etiology and Pathogenesis of Spondyloarthritis, 1307
80. Ankylosing Spondylitis and Other Forms of Axial Spondyloarthritis, 1319
81. Reactive Arthritis, 1344
82. Psoriatic Arthritis, 1359
83. Inflammatory Bowel Disease-Associated Arthritis and Other Enteropathic Arthropathies, 1381
• Part 11: Systemic Lupus Erythematosus and Related Syndromes
84. Etiology and Pathogenesis of Systemic Lupus Erythematosus, 1396
85. Clinical Features of Systemic Lupus Erythematosus, 1413
86. Treatment of Systemic Lupus Erythematosus, 1437
87. Antiphospholipid Syndrome, 1460
• Part 12: Systemic Sclerosis, Inflammatory Myopathies, and Overlap Syndromes
88. Etiology and Pathogenesis of Systemic Sclerosis, 1473
89. Clinical Features and Treatment of Scleroderma, 1499
90. Inflammatory Diseases of Muscle and Other Myopathies, 1539
91. Overlap Syndromes, 1569
• Part 13: Vasculitis
92. Classification and Epidemiology of Systemic Vasculitis, 1584
93. Giant Cell Arteritis, Polymyalgia Rheumatica, and Takayasu’s Arteritis, 1595
94. Anti-neutrophil Cytoplasmic Antibody- Associated Vasculitis, 1617
95. Polyarteritis Nodosa and Related Disorders, 1634
96. Immune Complex-Mediated Small Vessel Vasculitis, 1649
97. Primary Angiitis of the Central Nervous System, 1659
98. Behçet’s Disease, 1666
• Part 14: Crystal-Induced and Inflammasome- Mediated Inflammation
99. Pathogenesis of Inflammasome-Mediated Diseases, 1676
100. Etiology and Pathogenesis of Hyperuricemia and Gout, 1687
101. Clinical Features and Treatment of Gout, 1710
102. Calcium Crystal Disease: Calcium Pyrophosphate Dihydrate and Basic Calcium Phosphate, 1732
103. Familial Autoinflammatory Syndromes, 1752
• Part 15: Cartilage, Bone, and Heritable Connective Tissue Disorders
104. Pathogenesis of Osteoarthritis, 1770
105. Clinical Features of Osteoarthritis, 1789
106. Treatment of Osteoarthritis, 1803
107. Metabolic Bone Disease, 1819
108. Proliferative Bone Diseases, 1839
109. Osteonecrosis, 1852
110. Relapsing Polychondritis, 1876
111. Heritable Diseases of Connective Tissue, 1886
• Part 16: Rheumatic Diseases of Childhood
112. Etiology and Pathogenesis of Juvenile Idiopathic Arthritis, 1905
113. Clinical Features and Treatment of Juvenile Idiopathic Arthritis, 1911
114. Childhood-Onset Systemic Lupus Erythematosus, Drug-Induced Lupus in Children, and Neonatal Lupus, 1931
115.Juvenile Dermatomyositis, Scleroderma, Vasculitis, and Autoimmune Brain Disease, 1942
• Part 17: Infection and Arthritis
116. Bacterial Arthritis, 1979
117. Lyme Disease, 1994
118. Mycobacterial Infections of Bones and Joints, 2009
119. Fungal Infections of Bones and Joints, 2022
120. Rheumatic Manifestations of HIV Infection, 2033
121. Viral Arthritis, 2048
122. Rheumatic Fever and Post-streptococcal Arthritis, 2061
• Part 18: Arthritis Accompanying Systemic Disease
123. Amyloidosis, 2077
124. Sarcoidosis, 2088
125. Hemochromatosis, 2105
126. Hemophilic Arthropathy, 2115
127. Rheumatic Manifestations of Hemoglobinopathies, 2127
128. IgG4-Related Disease, 2135
129. Arthritis Accompanying Endocrine and Metabolic Disorders, 2149
130. Rheumatic Paraneoplastic Syndromes-Links Between Malignancy and Autoimmunity, 2161
131. Tumors and Tumor-like Lesions of Joints and Related Structures, 2167
132. Autoimmune Complications of Immune Checkpoint Inhibitors for Cancer, 2189
Index, I-1

Through 10 outstanding editions, Kelley & Firestein’s Textbook of Rheumatology has provided authoritative, in-depth guidance in rheumatology with an ideal balance of basic science and clinical application. The 11th Edition of this classic text continues this tradition of excellence, while keeping you abreast of recent advances in genetics and the microbiome, new therapies such as biologics and biosimilars, and other rapid changes in the field. It provides comprehensive, global coverage of all aspects of diagnosis, screening, and treatment in both adults and children, in a user-friendly, full color reference.

Authors
• Gary S. Firestein, MD, Distinguished Professor of Medicine, Dean and Associate Vice Chancellor of Translational Medicine, University of California San Diego School of Medicine, La Jolla, California.
• Ralph C. Budd, MD, Professor of Medicine and Microbiology and Molecular Genetics, Director, Vermont Center for Immunology and Infectious Diseases, University of Vermont College of Medicine Distinguished University Professor, The University of Vermont College of Medicine, Burlington, Vermont.
• Sherine E Gabriel, MD, MSc, Professor and Dean, Rutgers Robert Wood Johnson Medical School, CEO, Robert Wood Johnson Medical Group, Emeritus Professor, Mayo Clinic, New Brunswick, New Jersey.
• Iain B McInnes, PhD, FRCP, FRSE, FMedSci, Muirhead Professor of Medicine, Arthritis Research UK Professor of Rheumatology, Director of Institute of Infection,Immunity, and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
• James R O'Dell, MD, Bruce Professor and Vice Chairman of Internal Medicine, University of Nebraska Medical Center, Chief of Rheumatology, Department of Medicine, Omaha Veterans Affairs, Omaha, Nebraska.
• Gary Koretzky, Investigator and Director, Signal Transduction Program, AFCRI; Leonard Jarett Professor of Pathology and Laboratory Medicine; Chief, Division of Rheumatology